• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将低肌肉量纳入 IPS 系统及其对霍奇金淋巴瘤患者预后的意义。

Integration of low muscle mass into the IPS system and its prognostic significance in patients with Hodgkin's lymphoma.

机构信息

Department of Hematology, Adana City Research & Training Hospital, Adana, 01170, Turkey.

Department of General Surgery, Faculty of Medicine, Mersin University, Mersin, 33343, Turkey.

出版信息

Biomark Med. 2022 Feb;16(2):57-67. doi: 10.2217/bmm-2021-0696. Epub 2021 Nov 10.

DOI:10.2217/bmm-2021-0696
PMID:34753299
Abstract

The aim of this study is to determine whether a novel prognostic score can be obtained by including low muscle mass in the international prognostic score (IPS) system. Psoas muscle areas were determined in the PET/CT scans of the patients taken for staging at the time of diagnosis and after two cycles of ABVD. After evaluating the effect of low muscle mass on overall survival, receiver operating characteristic (ROC) analyzes were performed by including it in IPS systems. Overall survival was significantly lower in patients with low muscle mass. Adding low muscle mass to IPS scores increased AUC, sensitivity and specificity. The integration of low muscle mass into the IPS scoring systems increased the success of these systems in predicting a prognosis.

摘要

本研究旨在通过在国际预后评分(IPS)系统中纳入低肌肉量来确定是否可以获得新的预后评分。在诊断时进行分期的 PET/CT 扫描和 ABVD 两个周期后,确定了患者的竖脊肌区域。在评估低肌肉量对总生存的影响后,通过将其纳入 IPS 系统进行了接收者操作特征(ROC)分析。低肌肉量患者的总生存率明显降低。将低肌肉量加入 IPS 评分可提高 AUC、敏感性和特异性。将低肌肉量纳入 IPS 评分系统可提高这些系统预测预后的成功率。

相似文献

1
Integration of low muscle mass into the IPS system and its prognostic significance in patients with Hodgkin's lymphoma.将低肌肉量纳入 IPS 系统及其对霍奇金淋巴瘤患者预后的意义。
Biomark Med. 2022 Feb;16(2):57-67. doi: 10.2217/bmm-2021-0696. Epub 2021 Nov 10.
2
[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].国际预后评分在晚期霍奇金淋巴瘤预后预测中的应用可行性研究
Ai Zheng. 2006 Aug;25(8):1013-8.
3
Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.正电子发射断层扫描/计算机断层扫描测量的代谢肿瘤体积可作为早期霍奇金淋巴瘤确定治疗方式的临床参数。
Cancer Sci. 2013 Dec;104(12):1656-61. doi: 10.1111/cas.12282. Epub 2013 Oct 23.
4
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.生物标志物与中期PET扫描在预测经典型霍奇金淋巴瘤治疗结局中的联合作用:一项回顾性、欧洲多中心队列研究
Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.
5
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.在 Pet 引导治疗时代,晚期霍奇金淋巴瘤患者的经典预后因素失去了意义。
Ann Hematol. 2020 Feb;99(2):277-282. doi: 10.1007/s00277-019-03893-7. Epub 2019 Dec 23.
6
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.早期中期 PET 阳性的晚期霍奇金淋巴瘤患者单独接受 BEACOPP 或联合利妥昔单抗(HD18)治疗的无进展生存期:德国霍奇金研究组开展的一项开放标签、国际、随机 3 期研究。
Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.
7
The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG).霍奇金淋巴瘤中Ki-67和Bcl-2的表达:与国际预后评分及大包块病变的相关性:塞尔维亚淋巴瘤研究组(SLG)的一项研究
Med Oncol. 2007;24(1):45-53. doi: 10.1007/BF02685902.
8
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.ABVD 方案单用与放疗在局限期霍奇金淋巴瘤中的比较。
N Engl J Med. 2012 Feb 2;366(5):399-408. doi: 10.1056/NEJMoa1111961. Epub 2011 Dec 11.
9
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.局限期霍奇金淋巴瘤患者中ABVD化疗与包含放射治疗策略的随机对照研究:加拿大国立癌症研究所临床试验组和东部肿瘤协作组
J Clin Oncol. 2005 Jul 20;23(21):4634-42. doi: 10.1200/JCO.2005.09.085. Epub 2005 Apr 18.
10
A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma.一个包含血小板/淋巴细胞比值和国际预后评分 3 的新预后模型,用于预测未经治疗的晚期经典型霍奇金淋巴瘤患者的无进展生存。
Asia Pac J Clin Oncol. 2022 Oct;18(5):e486-e494. doi: 10.1111/ajco.13770. Epub 2022 Mar 3.

引用本文的文献

1
An integrative review of cancer-related cachexia and sarcopenia: A different focus in malignant hematology.癌症相关恶病质和肌肉减少症的综合综述:恶性血液学中的不同关注点。
Health Sci Rev (Oxf). 2024 Dec;13. doi: 10.1016/j.hsr.2024.100205. Epub 2024 Nov 14.
2
Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.血浆白蛋白在预后指标中的作用解读:文献综述
J Clin Med. 2023 Sep 22;12(19):6132. doi: 10.3390/jcm12196132.